Montelukast (Singulair) Dosing for Allergic Rhinitis
For allergic rhinitis, montelukast should be dosed once daily based on age: adults and adolescents ≥15 years take 10 mg, children 6-14 years take 5 mg chewable tablet, and children 2-5 years take 4 mg chewable tablet or oral granules. 1
Age-Based Dosing Recommendations
Adults and Adolescents (≥15 years)
- 10 mg tablet once daily
- Can be taken at any time of day, with or without food
- Timing can be individualized based on patient preference 1
Children 6-14 Years
- 5 mg chewable tablet once daily
- Approved for both seasonal and perennial allergic rhinitis 1
Children 2-5 Years
- 4 mg chewable tablet OR 4 mg oral granules once daily
- For seasonal allergic rhinitis only (safety not established for perennial allergic rhinitis in children <6 years) 1
- Oral granules can be given directly in mouth, mixed with cold/room temperature baby formula, breast milk, or soft foods (applesauce, carrots, rice, or ice cream)
- Must be administered within 15 minutes of opening packet 1
Infants 6-23 Months
- 4 mg oral granules once daily
- Approved only for perennial allergic rhinitis (not seasonal allergic rhinitis) 1
Important Clinical Context
Montelukast is NOT first-line therapy for allergic rhinitis. The 2017 Joint Task Force guidelines strongly recommend intranasal corticosteroids over montelukast for initial treatment of seasonal allergic rhinitis in patients ≥15 years, as intranasal corticosteroids demonstrate superior efficacy for nasal symptom reduction 2. Montelukast should be reserved for patients who have inadequate response or intolerance to alternative therapies 1.
Efficacy Considerations
- Montelukast is less effective than intranasal corticosteroids for allergic rhinitis 3
- Shows similar efficacy to oral antihistamines (particularly loratadine) 3
- Onset of action occurs by the second day of daily treatment 3
- Side effects are minimal 3
When to Consider Montelukast
Montelukast may be appropriate in specific clinical scenarios:
- Patients who cannot tolerate or refuse intranasal corticosteroids 2
- Patients with concurrent asthma and allergic rhinitis (can treat both conditions with single medication) 3
- Parents who are "steroid-phobic" in pediatric cases 3
- As combination therapy with antihistamines for patients unresponsive to monotherapy 3
Critical Safety Warning
The FDA has issued warnings about serious neuropsychiatric events with montelukast, including agitation, aggressive behavior, depression, sleep disturbances, suicidal thoughts and behavior 1. These events have occurred in adults, adolescents, and children with and without prior psychiatric history. Discuss these risks with patients and caregivers before prescribing, and advise them to monitor for behavioral changes 1.
Combination Therapy
If monotherapy fails, combination approaches include:
- Montelukast + oral antihistamine: Superior to either agent alone for symptom control 3, 4
- However, intranasal corticosteroids remain equal or superior to this combination 3
Dosing Pitfalls to Avoid
- Do not take additional doses within 24 hours 1
- Do not double dose if a dose is missed - simply take the next scheduled dose 1
- For patients taking montelukast for asthma, do not add an additional dose for allergic rhinitis - one daily dose treats both conditions 1
- Oral granules must not be stored after opening - discard unused portions 1